Auditory Slow Wave Enhancement in Parkinson Disease and Mild Cognitive Impairment

University of Zurich48 enrolled

Overview

The study aims to assess the efficacy of auditory slow-wave sleep (SWS) enhancement in PD patients and patients with amnestic MCI. Patients will be randomized to two groups: Group 1 will first be treated with auditory stimulation for two weeks and then - after a washout period - switched to two weeks of sham stimulation. Group 2 will first receive sham stimulation for two weeks and then - after a washout period - switch to two weeks of auditory stimulation treatment. The washout period in between will be 2-4 weeks.

The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy of auditory slow-wave sleep (SWS) enhancement in PD patients and patients with amnestic MCI. The screening phase includes entry questionnaires about inclusion/exclusion criteria, sleep quality, chronotype, and handedness, and 1-4 screening nights at home with the TSB Axo, to allow for stimulation optimization. One of the screening nights will be extended to screen for sleep apnea and periodic limb movements during sleep using an ambulatory screening device. Upon final inclusion, 24 PD and 24 MCI patients will be enrolled in the study for an overall period of 6-8 weeks (not including screening phase). Patients will receive 2 weeks of auditory SWS enhancement and 2 weeks of sham stimulation (only device application, no tones played) in a counter-balanced cross-over design, with a 2-4 week washout period during cross-over. Study visits will be performed immediately before and after each intervention period, i.e. after 2 weeks of auditory stimulation or sham stimulation, respectively. Study visits will include standardized clinical examinations, symptom questionnaires, blood sampling after intervention and screening for adverse events by a study physician. Study visits will take place at the Department of Neurology, University Hospital Zurich.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Parkinson Disease Mild Cognitive Impairment

Interventions

TSB AxoDEVICE

The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PD: Diagnosis of PD along international criteria, with mild to moderate disease severity (Hoehn and Yahr scale, stages ll-lll) * PD: Ability to apply the intervention for the duration of study * MCI: Diagnosis of MCI along international criteria, with a predominant amnestic presentation (single- or multi-domain amnestic MCI) * MCI: Presence of a cohabitant person who could assist with the application * MCI: Ability to apply the intervention for the duration of study, with assistance of co-habitant if needed PD and MCI: * Age above 18 years * Informed consent as documented by signature * Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study * Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes * Dosing of dopaminergic, cholinergic, and other PD or MCI medication must have been stable for at least 14 days prior to start of the first intervention * Negative pregnancy test during screening (except in women who are surgically sterilized/hysterectomized or postmenopausal for longer than 1 year) Exclusion Criteria: * PD: Presence of neurologic, psychiatric, or sleep disorders (others than associated with PD) * PD: Parkinsonism without response to levodopa; Atypical Parkinsonian syndromes * PD: Cognitive impairment (Montréal Cognitive Assessment \[MoCA\] \<24) * MCI: Present diagnosis of a neurological (other than MCI) or interfering psychiatric disease or sleep disorder (e.g. sleep apnoea syndrome, restless legs syndrome) PD and MCI: * Severe medical conditions as renal insufficiency, liver failure or congestive heart failure * Regular use of the following drugs: Benzodiazepines and other central nervous system (CNS)-depressant substances, melatonin and other sleep inducing substances, approved drugs for Alzheimer-type dementia (acetylcholine-esterase inhibitor, memantine) * Inability to hear the tones produced by the TSB Axo * Skin disorders/problems/allergies in face/ear area that could worsen with electrode application * Known or suspected drug- or medication abuse * Known or suspected non-compliance * Participation in another study with investigational drug or investigational medical devices within the 30 days preceding and during the present study * Previous enrolment in the current study * Enrolment of the investigator, his/her family members, employees and other dependent persons * Shift work (work during the night) * Travelling more than 2 time zones in the last month before intervention starts or during intervention (start of intervention will be adapted to fit with this criteria) * Substance or alcohol abuse (i.e. \> 0.5 l wine or 1 l beer per day) * High caffeine consumption (\> 5 servings/day; including coffee, energy drink) * Implanted deep brain stimulation electrodes * Women who are pregnant or breast feeding * Intention to become pregnant during the course of the study * Lack of safe contraception, defined as: Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases

Locations (1)

University Hospital Zurich, Neurology department

Zurich, Switzerland

RECRUITING

Outcomes

Primary Outcomes

Difference in objective EDS

Difference in objective excessive daytime sleepiness (EDS), measured with Multiple Sleep Latency Test (MSLT; minutes), in Parkinson patients

Time frame: assessed after each intervention (day 15 of each intervention)

Difference in verbal episodic memory performance

Difference in verbal episodic memory performance, measured with the Hopkins Verbal Learning Test (HVLT; score ranges from 0 to 12, higher scores indicate better performance) delayed recall, in Mild Cognitive Impairment patients

Time frame: assessed after each intervention (day 15 of each intervention)

Secondary Outcomes

Subjective EDS

Change in subjective excessive daytime sleepiness (EDS), measured with the Epworth Sleepiness Scale (ESS; score ranges from 0 to 24, higher scores indicate greater EDS)

Time frame: assessed before and after each intervention (day 1 and 15 of each intervention)

Sustained attention

Sustained attention, measured with the Sustained Attention to Response Task (SART)

Time frame: assessed after each intervention (day 15 of each intervention)

Vigilance

Vigilance, measured with the Psychomotor Vigilance Task (PVT)

Time frame: assessed after each intervention (day 15 of each intervention)

Subjective nocturnal sleep quality

Subjective nocturnal sleep quality, measured with the Parkinson's Disease Sleep Scale -2 (PDSS-2; score ranges from 0 to 60, higher scores indicate worse sleep quality) in PD patients and Pittsburgh Sleep Quality Index (PSQI; score ranges from 0 to 21, higher scores indicate worse sleep quality) in MCI patients

Central Contacts

Jana Horlacher, MD

CONTACT

+41432535022 jana.horlacher@usz.ch

Angelina Maric, PhD

CONTACT

+41442558615 angelina.maric@usz.ch

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.